Introduction - Since late 2013, direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C. Access to these drugs has gradually been expanded to all chronic carriers. In the context of France’s goal to eliminate hepatitis C by 2025, this study aimed to examine trends in the number and characteristics of patients who initiated DAA treatment between 2014 and 2017. Methods - Data on the initiation of DAA treatment for the years 2014 to 2017 in mainland France were extracted from the National Health Data System (SNDS) for all health insurance schemes. Results - Between 2014 and 2017, 58,943 patients initiated DAA treatment: 11,500 in 2014, 13,904 in 2015, 14,291 in 2016, and 19,248 in 2017. Between 2014/2015 and 2016/2017, the median age of patients decreased from 56 to 54 years, and the proportion of men fell from 65% to 57%. Île-de-France and Provence-Alpes-Côte d'Azur were the regions with the highest numbers of patients who initiated treatment relative to the population in 2017. Conclusion - Universal access to direct-acting antivirals (DAAs) led to a significant increase in the number of patients who initiated treatment between 2016 and 2017 (+35%) and to the treatment of younger patients and, more often, women. These data also show that the goal of treating 120,000 patients by 2022 is halfway achieved. Efforts must nevertheless continue to enable the elimination of hepatitis C.